AN2 Therapeutics, Inc. (ANTX)
NASDAQ$1.27
Market Cap
$38.23M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
101 of 896
Rank in Industry
70 of 514
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ANTX Insider Trading Activity
ANTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $2,043,337 | 12 | 71 |
Sells | $3,830,711 | 5 | 29 |
Related Transactions
| Leonard Braden Michael | 10 percent owner | 1 | $1.56M | 0 | $0 | $1.56M |
| Readnour Robin Shane | director | 7 | $405,521 | 0 | $0 | $405,521 |
| Easom Eric | Chief Executive Officer | 1 | $49,970 | 0 | $0 | $49,970 |
| Zakrzewski Joseph S | director | 3 | $27,846 | 0 | $0 | $27,846 |
| Prior Stephen David | Chief Strategy Officer | 0 | $0 | 1 | $2,721 | $-2,721 |
| Chanda Sanjay | Chief Development Officer | 0 | $0 | 1 | $3,965 | $-3,965 |
| Day Lucy | Chief Financial Officer | 0 | $0 | 1 | $3,965 | $-3,965 |
| Eizen Joshua M | See Remarks | 0 | $0 | 1 | $12,958 | $-12,958 |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 0 | $0 | 1 | $3.81M | $-3.81M |
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Insider Activity of AN2 Therapeutics, Inc.
Over the last 12 months, insiders at AN2 Therapeutics, Inc. have bought $2.04M and sold $3.83M worth of AN2 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at AN2 Therapeutics, Inc. have bought $13.66M and sold $5.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $1.56M. Readnour Robin Shane (director) — $405,521. Easom Eric (Chief Executive Officer) — $49,970.
The last purchase of 10,000 shares for transaction amount of $14,930 was made by Readnour Robin Shane (director) on 2024‑12‑10.
List of Insider Buy and Sell Transactions, AN2 Therapeutics, Inc.
| 2025-01-03 | Sale | Eizen Joshua M | See Remarks | 9,663 0.0304% | $1.34 | $12,958 | -11.62% | |
| 2025-01-03 | Sale | Prior Stephen David | Chief Strategy Officer | 2,029 0.0064% | $1.34 | $2,721 | -11.62% | |
| 2025-01-03 | Sale | Day Lucy | Chief Financial Officer | 2,957 0.0093% | $1.34 | $3,965 | -11.62% | |
| 2025-01-03 | Sale | Chanda Sanjay | Chief Development Officer | 2,957 0.0093% | $1.34 | $3,965 | -11.62% | |
| 2024-12-10 | Readnour Robin Shane | director | 10,000 0.0329% | $1.49 | $14,930 | -15.23% | ||
| 2024-12-09 | Readnour Robin Shane | director | 30,772 0.104% | $1.43 | $43,984 | -9.15% | ||
| 2024-12-06 | Readnour Robin Shane | director | 19,228 0.0635% | $1.45 | $27,795 | -10.07% | ||
| 2024-11-27 | Readnour Robin Shane | director | 50,000 0.142% | $1.42 | $70,840 | -3.28% | ||
| 2024-11-27 | Zakrzewski Joseph S | director | 2,000 0.0056% | $1.40 | $2,800 | -3.28% | ||
| 2024-11-26 | Readnour Robin Shane | director | 25,000 0.0698% | $1.39 | $34,845 | -4.32% | ||
| 2024-11-20 | Readnour Robin Shane | director | 50,000 0.116% | $1.16 | $57,870 | +3.08% | ||
| 2024-11-19 | Readnour Robin Shane | director | 150,000 0.3112% | $1.04 | $155,258 | +25.94% | ||
| 2024-11-19 | Zakrzewski Joseph S | director | 5,000 0.0101% | $1.01 | $5,050 | +25.94% | ||
| 2024-11-18 | Easom Eric | Chief Executive Officer | 50,000 0.1001% | $1.00 | $49,970 | +33.00% | ||
| 2024-11-18 | Zakrzewski Joseph S | director | 20,000 0.0401% | $1.00 | $19,996 | +33.00% | ||
| 2024-08-14 | Leonard Braden Michael | 10 percent owner | 1.5M 3.1264% | $1.04 | $1.56M | +8.10% | ||
| 2024-08-09 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 3.53M 7.6298% | $1.08 | $3.81M | +10.15% | |
| 2024-01-18 | Sale | Zakrzewski Joseph S | director | 100,000 3.8307% | $19.11 | $1.91M | -89.57% | |
| 2024-01-16 | Sale | Aziz Kabeer | director | 100,000 3.9381% | $19.65 | $1.97M | -89.74% | |
| 2024-01-16 | Sale | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 100,000 3.9381% | $19.65 | $1.97M | -89.74% |
Total: 78
*Gray background shows transactions not older than one year
Insider Historical Profitability
2.74%
| Leonard Braden Michael | 10 percent owner | 5749432 19.1019% | $7.3M | 1 | 0 | |
| Easom Eric | Chief Executive Officer | 1065766 3.5409% | $1.35M | 2 | 17 | +61.1% |
| Readnour Robin Shane | director | 652573 2.1681% | $828,767.71 | 8 | 2 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 300853 0.9996% | $382,083.31 | 9 | 1 | +3.7% |
| Zakrzewski Joseph S | director | 125199 0.416% | $159,002.73 | 3 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$140,938,207 | 36 | 14.75% | $39.48M | |
$6,787,959 | 35 | 49.84% | $41.73M | |
$459,011,221 | 33 | 33.04% | $37.75M | |
$241,165 | 22 | -16.72% | $40.24M | |
$1,087,418 | 21 | 1.95% | $41.58M |
ANTX Institutional Investors: Active Positions
| Increased Positions | 23 | +67.65% | 5M | +34.18% |
| Decreased Positions | 14 | -41.18% | 5M | -33.59% |
| New Positions | 11 | New | 3M | New |
| Sold Out Positions | 7 | Sold Out | 4M | Sold Out |
| Total Postitions | 43 | +26.47% | 14M | +0.59% |
ANTX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bml Capital Management, Llc | $7,992.00 | 19.17% | 5.75M | 0 | 0% | 2024-12-31 |
| Almitas Capital Llc | $1,825.00 | 4.38% | 1.31M | +1M | New | 2024-12-31 |
| Vanguard Group Inc | $1,440.00 | 3.45% | 1.04M | -5,580 | -0.54% | 2024-12-31 |
| Renaissance Technologies Llc | $806.00 | 1.93% | 579,773 | +155,973 | +36.8% | 2024-12-31 |
| Peapod Lane Capital Llc | $805.00 | 1.93% | 578,825 | +578,825 | New | 2024-12-31 |
| Two Sigma Advisers, Lp | $734.00 | 1.76% | 528,300 | +407,400 | +336.97% | 2024-12-31 |
| Bank Of Montreal /Can/ | $587.00 | 1.41% | 422,077 | +422,077 | New | 2024-12-31 |
| Two Sigma Investments, Lp | $556.00 | 1.33% | 400,332 | +222,492 | +125.11% | 2024-12-31 |
| Bank Of Nova Scotia | $549.00 | 1.32% | 394,868 | +394,868 | New | 2024-12-31 |
| Bank Of America Corp /De/ | $536.00 | 1.29% | 385,475 | +369,265 | +2,278.01% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.